[Cerebral and peripheral consumption of L-5-HTP in patients with manic, depressive or psychotic syndromes].
D006916:5-Hydroxytryptophan / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism* / Q000652:urine; D000328:Adult; D001714:Bipolar Disorder / Q000378:metabolism*; D001921:Brain / Q000378:metabolism; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000652:urine; D007275:Injections, Intravenous; D007601:Jugular Veins; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000378:metabolism; D010300:Parkinson Disease / Q000378:metabolism; D012701:Serotonin / Q000652:urine
D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D004295:Dihydroxyphenylalanine; D006916:5-Hydroxytryptophan; D002262:Carboxy-Lyases
Consommation cérébrale et périphérique de L-5-HTP chez les patients atteints de syndromes maniaques, dépressifs ou psychotiques